

## [Ethosuximide](#)

Essential medicine status

Section:

[5. Medicines for neurological disorders](#) [5.1. Medicines for central nervous system disorders](#) [5.1.1. Antiseizure medicines](#)

ATC codes: [N03AD01](#)

EMLc

Indication

Absence seizures, typical ICD11 code: [8A68.2](#)

INN

Ethosuximide

Medicine type

Device

List type

Complementary

Formulations

**Oral > Liquid:** 250 mg per 5 mL

**Oral > Solid:** 250 mg

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1987 ([TRS 770](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 950](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Ethosuximide](#)

DrugBank

[Ethosuximide](#)

Summary of evidence and Expert Committee recommendations

The EMLc Subcommittee endorsed the inclusion of ethosuximide on the complementary list of the EMLc for treatment of absence seizures in children.